Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)
Sponsor: Petrov, Andrey
Summary
The objective of this pilot study is to evaluate the efficacy of adding S-Gboxin to standard RT/TMZ treatment protocols in patients with glioblastoma multiforme (GBM) or midline glioma (DMG), regardless of their mutation status
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-05-20
Completion Date
2027-12-10
Last Updated
2026-06-03
Healthy Volunteers
No
Conditions
Interventions
S-Gboxin
Gboxin specifically inhibits the growth of human glioblastoma cells but not normal cells. Gboxin rapidly and irreversibly impairs oxygen consumption in glioblastoma cells. Its positive charge for binding to mitochondrial oxidative phosphorylation complexes is dependent on the proton gradient of the inner mitochondrial membrane, and it inhibits F 0 F 1 ATP synthase activity in tumor cells. S-Gboxin crosses the blood-brain barrier at therapeutically effective concentrations.
Locations (3)
Tbilisi Cancer Centre
Tbilisi, Georgia
Kazakh Institute of Oncology and Radiology
Almaty, Kazakhstan
National Cancer Institute
Kyiv, Ukraine